. Author manuscript; available in PMC: 2021 Mar 1.

Published in final edited form as: Best Pract Res Clin Haematol. 2020 Jan 25;33(1):101152. doi: 10.1016/j.beha.2020.101152

Table 4:

Selected variables described in the literature to identify high-risk SMM

Type of measurement	Parameter	Reference
Tumor burden	M-protein level	[2, 15, 17]
	Bone marrow plasma cell percentage	[2, 17]
	Involved: uninvolved serum free light chain ratio	[16, 17]
	Blood circulating plasma cells	[29, 30]
Immunology Biology Genetics	Serum immunoparesis	[2, 15]
	Percentage of aberrant plasma cells of all plasma cells in bone marrow aspirate	[15]
	Evolving disease: evolving M-protein, evolving hemoglobin, evolving sFLC	[21–24, 57]
	Cytogenetics	[27, 28]
	Gene expression profiling	[20, 58]
	FISH	[27, 28]
Imaging	MRI	[31]
Imaging	PET/CT	[59]

Abbreviations: FISH, Fluorescence in situ hybridization; MRI, Magnetic resonance imaging; PET/CT, positron emission tomography – computed tomography; sFLC, serum free-light chain ratio